Sinopharm Holdings (01099): Sinopharm's net profit for the first half of the year was 606 million yuan, down 8.97% year on year

Zhitong Finance App News, Sinopharm Holdings (01099) announced Sinopharm's consistent 2026 semi-annual performance report, achieving operating income of RMB 36.266 billion, down 1.44% year on year; operating profit of RMB 834 million, down 9.94% year on year; total profit of RMB 827 million, down 9.88% year on year; net profit attributable to shareholders of listed companies was RMB 606 million, down 8.97% year on year. The corresponding basic earnings per share fell 9.17% year on year. Revenue and profit showed a decline compared to the first quarter The trend was narrowing, and the weighted average return on net assets fell 0.49 percentage points year over year.

In the first half of 2026, the distribution sector achieved revenue of RMB 26.539 billion, a year-on-year decrease of 0.91%; net profit of RMB 460 million, a year-on-year decrease of 4.56%. Despite being affected by the continued deepening of industry policies and short-term pressure on sector operations, Sinopharm has continued to narrow the decline in revenue and profit through increased growth, structural adjustments, and refined controls, showing good business resilience. The retail sector (i.e. “National University Pharmacy”) achieved operating revenue of RMB 10.227 billion, a year-on-year decrease of 2.40%, and the decline narrowed; realized net profit of RMB 0.13 billion, a year-on-year decrease of 19.74%. Due to factors such as industry policy adjustments and increased market competition, the sales revenue of National University Pharmacies declined slightly; combined with changes in the sales structure, the share of sales of high-margin varieties decreased, and gross profit decreased, leading to a decline in profits.